Keliximab

Keliximab is a monoclonal antibody designed for the treatment of autoimmune diseases. It is classified under the immunoglobulin G (IgG) class of antibodies and specifically targets the CD4 molecule found on the surface of certain T cells.

Mechanism of Action[edit | edit source]

Keliximab works by binding to the CD4 molecule on T cells. This binding inhibits the interaction between T cells and antigen-presenting cells, thereby reducing the immune response that leads to the symptoms of autoimmune diseases.

Clinical Trials[edit | edit source]

Keliximab has been tested in several clinical trials for its efficacy in treating autoimmune diseases such as rheumatoid arthritis and psoriasis. However, the results have been mixed, with some trials showing significant improvement in symptoms, while others showed no significant difference compared to placebo.

Side Effects[edit | edit source]

Like all drugs, Keliximab has potential side effects. These can include infection due to the suppression of the immune system, allergic reactions to the drug, and potential cardiovascular effects.

Future Research[edit | edit source]

While Keliximab has shown promise in treating autoimmune diseases, more research is needed to fully understand its potential benefits and risks. Future research may focus on optimizing the dosage and administration of the drug, as well as exploring its potential use in other autoimmune diseases.